Tags

Type your tag names separated by a space and hit enter

Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Rev Med Virol. 2020 09; 30(5):e2136.RM

Abstract

SARS-CoV-2 has caused a pandemic which is putting strain on the health-care system and global economy. There is much pressure to develop both preventative and curative therapies for SARS-CoV-2 as there is no evidence to support therapies to improve outcomes in patients with SARS-CoV-2. Medications that inhibit certain steps of virus life cycle that are currently used to treat other illnesses such as Malaria, Ebola, HIV and Hepatitis C are being studied for use against SARS-CoV-2. To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections.

Links

Publisher Full Text
ncbi.nlm.nih.gov
doi.org
PMC Free PDF
Aggregator Full Text

Authors+Show Affiliations

Giovane RA
Department of Family Medicine, Regional Medical Center of Central Alabama, Greenville, Alabama, USA.
Rezai S
Department of OB/GYN, Valley Community Healthcare, North Hollywood, California, USA.
Cleland E
Department of Family Medicine, University of Alabama, Tuscaloosa, Alabama, USA.
Henderson CE
Garden OB/GYN, Mercy Medical Center, New York, New York, USA.

MeSH

Adenosine MonophosphateAlanineAngiotensin-Converting Enzyme 2Antibodies, Monoclonal, HumanizedAntiviral AgentsBetacoronavirusCOVID-19Coronavirus InfectionsDisease ProgressionDrug CombinationsDrug RepositioningGabexateGene Expression RegulationHost-Pathogen InteractionsHumansHydroxychloroquineIndolesLopinavirPandemicsPeptidyl-Dipeptidase APneumonia, ViralRitonavirSARS-CoV-2Spike Glycoprotein, Coronavirus

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32644275

Citation

Giovane, Richard A., et al. "Current Pharmacological Modalities for Management of Novel Coronavirus Disease 2019 (COVID-19) and the Rationale for Their Utilization: a Review." Reviews in Medical Virology, vol. 30, no. 5, 2020, pp. e2136.
Giovane RA, Rezai S, Cleland E, et al. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Rev Med Virol. 2020;30(5):e2136.
Giovane, R. A., Rezai, S., Cleland, E., & Henderson, C. E. (2020). Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Reviews in Medical Virology, 30(5), e2136. https://doi.org/10.1002/rmv.2136
Giovane RA, et al. Current Pharmacological Modalities for Management of Novel Coronavirus Disease 2019 (COVID-19) and the Rationale for Their Utilization: a Review. Rev Med Virol. 2020;30(5):e2136. PubMed PMID: 32644275.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. AU - Giovane,Richard A, AU - Rezai,Shadi, AU - Cleland,Ellen, AU - Henderson,Cassandra E, Y1 - 2020/07/09/ PY - 2020/04/30/received PY - 2020/06/01/revised PY - 2020/06/02/accepted PY - 2020/7/10/pubmed PY - 2020/10/2/medline PY - 2020/7/10/entrez KW - 2019-nCoV KW - COVID-19 KW - Lopinavir/Ritonavir KW - RNA-dependent RNA polymerase inhibitors KW - Remdesivir KW - SARS CoV-2 KW - SARS coronavirus (SARS-CoV) KW - Umifenovir KW - acetazolamide KW - acute respiratory distress syndrome (ARDS) KW - autoimmune KW - camostat mesylate KW - chloroquine KW - high altitude pulmonary edema (HAPE) KW - hydroxychloroquine KW - novel coronavirus 2019 KW - pandemic KW - severe acute respiratory syndrome (SARS) SP - e2136 EP - e2136 JF - Reviews in medical virology JO - Rev Med Virol VL - 30 IS - 5 N2 - SARS-CoV-2 has caused a pandemic which is putting strain on the health-care system and global economy. There is much pressure to develop both preventative and curative therapies for SARS-CoV-2 as there is no evidence to support therapies to improve outcomes in patients with SARS-CoV-2. Medications that inhibit certain steps of virus life cycle that are currently used to treat other illnesses such as Malaria, Ebola, HIV and Hepatitis C are being studied for use against SARS-CoV-2. To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections. SN - 1099-1654 UR - https://www.unboundmedicine.com/medline/citation/32644275/Current_pharmacological_modalities_for_management_of_novel_coronavirus_disease_2019__COVID_19__and_the_rationale_for_their_utilization:_A_review_ L2 - https://doi.org/10.1002/rmv.2136 DB - PRIME DP - Unbound Medicine ER -